Myeloproliferative Disorders
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Subtype terms (8)
More specific conditions that are subtypes of Myeloproliferative Disorders in the MeSH hierarchy.
- Anemia, Myelophthisic
- Leukemia, Erythroblastic, Acute
7 drugs (6 approved, 1 experimental)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
260 drugs (137 approved, 123 experimental)
- Leukemia, Neutrophilic, Chronic
37 drugs (32 approved, 5 experimental)
- Leukemoid Reaction
- Polycythemia Vera
117 drugs (66 approved, 51 experimental)
- Primary Myelofibrosis
232 drugs (126 approved, 106 experimental)
- Thrombocytosis
13 drugs (11 approved, 2 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 3 trials (52)
- decitabine
- tioguanine
- mercaptopurine
- plerixafor
- amitriptyline
- urea
- epoetin
- ketamine
- deoxycholic acid
- tacrolimus
- ginseng
- naltrexone
- bone marrow derived mesenchymal stem cells
- haploidentical mononuclear cells
- hydroxyurea
- hypericum perforatum
- idarubicin
- Filgrastim
- luspatercept
- nystatin
- carboplatin
- allogeneic hematopoietic stem cells
- ruxolitinib
- sirolimus
- cyclosporine
- acetylsalicylic acid
- mycophenolate
- cyclophosphamide
- daunorubicin
- allogeneic lymphocytes
- +22 more
Phase 2 trials (143)
- allopurinol
- cladribine
- thalidomide
- azacitidine
- vitamin d3
- methylprednisolone
- lysergic acid diethylamide
- adct-301
- cmv-specific t-cells
- dexrazoxane
- allogeneic natural killer cells
- vitamin e
- amifostine
- Eprenetapopt
- acetylcysteine
- mk-1775
- sorafenib
- venetoclax
- bendamustine
- mirabegron
- bi213 m195
- bkt-140
- bone autograft
- captopril
- lenalidomide
- clofarabine
- quizartinib
- prednisone
- succimer
- doxorubicin
- +113 more
Phase 1 trials (87)
- 7-hydroxystaurosporine
- afatinib
- olaparib
- belinostat
- bpx-501
- cd25-depleted peripheral blood mononuclear cell
- cilengitide
- nelarabine
- fostemsavir
- enzalutamide
- n-(4-hydroxyphenyl)all-trans retinamide
- fluorouracil
- trametinib
- hum-195/rgel
- myeloid progenitor cells
- idelalisib
- il-7
- incb057643
- nivolumab
- lenvatinib
- a27.15
- monoclonal antibody e2.3
- montanide isa51
- motexafin gadolinium
- navitoclax
- palbociclib
- panobinostat
- pemetrexed
- perifosine
- plx51107
- +57 more
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (43)
- Incyte
- Celgene
- Kiadis Pharma
- Aronex Pharmaceuticals
- Center for International Blood and Marrow Transplant Research
- Medical Research Council
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- European Working Group of MDS in Childhood
- Canadian Cancer Trials Group
- Case Western Reserve University
- University of London
- Cornell University
- Dartmouth University
- University of Washington
- Johns Hopkins University
- Leukemia Research Foundation
- Medical College of Wisconsin
- Oregon Health and Science University
- Rutgers University
- The Canadian Blood and Marrow Transplant Group
- University of Kansas
- University of Michigan
- University of Toronto
- University of Birmingham
- Mayo Clinic
- Cardiff University
- University of California, Los Angeles
- Vanderbilt University
- +13 more
Organization Involved with Phase 2 Indications (99)
- S*BIO
- ADC Therapeutics SARL
- AbbVie
- Jazz Pharmaceuticals
- Amgen
- Astellas
- Eli Lilly
- Novartis
- Aprea Therapeutics AB
- Bayer
- Bellicum Pharmaceuticals
- BioLineRx, Ltd.
- CTI BioPharma
- Cellphire, Inc.
- Galena Biopharma, Inc.
- Italfarmaco
- Onconova Therapeutics, Inc.
- Polyphor Ltd.
- Vion Pharmaceuticals
- Agios Pharmaceuticals, Inc.
- National Institutes of Health (NIH)
- University of Pennsylvania
- Baylor University
- Cancer Biotherapy Research Group
- Cancer Treatment Centers of America
- Harvard University
- Eastern Cooperative Oncology Group
- Drexel University
- Duke University
- Emory University
- +69 more
Organization Involved with Phase 1 Indications (35)
- Seattle Genetics
- Pharmacyclics
- Exelixis
- MediGene
- Genzyme
- Constellation Pharmaceuticals
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Regimmune Inc.
- Synta Pharmaceuticals Corp.
- Epizyme, Inc.
- Ziopharm
- University of Arizona
- University of Pittsburgh
- AIDS Malignancy Consortium
- HonorHealth Research Institute
- New York University
- Ohio State University
- University of Maryland
- University of Southern California
- Yale University
- Peking University
- University of California, Berkeley
- Leiden University
- Loxo Oncology
- Astex Pharmaceuticals, Inc.
- SCRI Development Innovations
- Erasmus University Rotterdam
- The Leukemia and Lymphoma Society
- Vasgene Therapeutics, Inc
- L K Whittier Foundation
- +5 more
Organization Involved with Other Experimental Indications (4)